MONDRIAN Study on Early-stage Non-small Cell Lung Cancer Combining Clinical and Molecular Data to Predict Response to Stereotactic Body Radiotherapy or Surgery
Led by European Institute of Oncology · Updated on 2024-09-23
270
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating early-stage non-small cell lung cancer NSCLC, focusing on why some patients respond well to Stereotactic Body Radiotherapy SBRT while others do not. This observational study aims to identify clinical, imaging, and biological factors that may predict how patients will respond to SBRT. The study compares patients treated with SBRT to those treated with surgery to understand which factors indicate disease behavior and treatment response.
Participants will receive either SBRT or surgery based on the best clinical practices. SBRT is a high-precision radiation treatment delivered in 3-5 sessions, with doses tailored to patient and tumor characteristics like lung health and tumor location. Surgery involves pulmonary anatomical resection and lymph node removal. Both treatment groups will contribute data for advanced analyses, including imaging, gene expression, and proteomics, to build predictive models.
During the 60-month study, participants will have routine clinical data collected, including scans CT and PET, blood tests, and tissue analysis from tumors or biopsies. Researchers will use this information to develop complex models predicting disease progression and treatment outcomes. The main outcome measured is progression-free survival over 24 months. The study also applies advanced techniques like deep neural networks and federated learning to integrate data from multiple sources and reduce bias.
CONDITIONS
Brief Title
MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
Research Team
S
Stefania Volpe, MD, PhD
C
Cristiana Fodor, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically proven non-small cell lung cancer (NSCLC), any histology type
Clinical stage I or II according to AJCC TNM classification (8th Edition)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
No absolute contraindications to surgery or SBRT
Ability and willingness to sign informed consent for treatment and study participation
You will not qualify if you...
Prior invasive cancer diagnosed within 3 years before early-stage NSCLC diagnosis
Mental or psychiatric disorders preventing valid informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Varies according to treatment type
Participants receive either stereotactic body radiotherapy (SBRT) over 3 to 5 fractions or undergo pulmonary anatomical surgery with lymph node dissection.
3 to 5 treatment sessions for SBRT or 1 surgical procedure with hospital stay
Monitoring
Duration - Up to 24 months
Participants are observed with routine clinical data collection including imaging and molecular analyses to assess disease progression and treatment response.
Visits for imaging and sample collection as per clinical follow-up schedule
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Study of MK-1084 Combined With Other Treatments for Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with KRAS G12C Mutations
Evaluating the Benefits of Photon Counting CT with Spectral Information for Patients Suspected of Lung Cancer
Evaluating Needle-Based Confocal Laser Endomicroscopy During Bronchoscopy
for Diagnosing Peripheral Lung Nodules in Adults
Improving Health Outcomes by Early COPD Diagnosis and Treatment in Patients Being Evaluated for Lung Cancer
Study of Intestinal Low-Dose Radiotherapy Combined with PD-1PD-L1 Immunotherapy for Adults with Metastatic Solid Tumors Resistant to Previous Immunotherapy
MONDRIAN Study on Early-stage Non-small Cell Lung Cancer Combining Clinical and Molecular Data to Predict Response to Stereotactic Body Radiotherapy or Surgery
Safety and Feasibility of Preoperative Sintilimab, Bevacizumab, and Chemotherapy in Treating Locally Advanced Resectable Non-Small Cell Lung Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.